Cell Therapeutics, Inc. (NASDAQ:CTIC)

CAPS Rating: 2 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Recs

0
Player Avatar Brian7992 (< 20) Submitted: 8/20/2009 7:40:30 AM : Outperform Start Price: $10.08 CTIC Score: -123.57

Best Bio Bets

Featured Broker Partners


Advertisement